VIDAS® Cardiac Assays
Improve Patient Outcomes and Optimize Patient Management in the Emergency Department
An easy access to innovative cardiac tests for acute and complex situations to deliver reliable, fast, and actionable results to clinicians. bioMérieux with VIDAS® provides a comprehensive emergency & critical care offer for better patient with cardiovascular disease management in the emergency department.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
- Image
- Overview
- Assays
- Resources
Overview
Cardiovascular diseases are the leading cause of death worldwide. According to WHO estimates, they caused 17.9 million deaths in 2019, representing 32% of all deaths. Of these deaths, 85% were due to heart attack and stroke.
Cardiovascular diseases have a major impact on the length and quality of life of those affected, but also on public health spending and the national economy.
Heart Failure
Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64 million people globally. Although the incidence of HF has stabilised worldwide and seems to be declining in developed countries, the prevalence is increasing due to the ageing of the population, improved survival after MI, and improved treatment and survival of patients with HF.1
In acute heart failure, any delay in initiation of treatment increases mortality. Prompt and adequate diagnosis is a clinical challenge. International guidelines recommend the use of B-type natriuretic peptide testing in the diagnostic workup of Heart Failure (HF) in both acute myocardial infarction and non-acute patient presentation.
In the emergency department (ED), NT-proBNP is particularly useful for the triage of patients with acute dyspnea and suspected acute HF. It is highly sensitive and specific for exclusion (single rule-out cut-off value of 300 pg/mL) or confirmation of acute HF (age-adjusted rule-in cut-off values).
VIDAS® NT-proBNP2 is a useful tool for rapid clinical assessment and diagnosis of patients with symptoms of suspected heart failure.
- High sensitivity and specificity
- Allows initiation of timely, appropriate treatment
- Cost-effective tool adapted to emergency situations
VIDAS® NT-proBNP2 to aid in the diagnosis of suspected heart failure for timely and appropriate treatment.
Acute Coronary Syndromes
Did you know? Every year, 16 million people worldwide die of cardiovascular diseases, specifically heart attacks or stroke2. Chest pain is among the top 10 reasons to visit an emergency department (ED), accounting for about 5% of all ED visits3. Expected prevalence of acute myocardial infarction (MI) in chest pain patients in the ED is between 5 and 10% for ST-segment elevation MI (STEMI) and 15 and 20% for non-ST segment elevation MI (NSTEMI)4.
The protein concentration of the MB isoenzyme of human creatine kinase (CK-MB) also increases rapidly after infarction. Due to its shorter half-life, it can be used as a marker for re-infarction.
Myoglobin is one of the first markers of myocardial damage to be measured after the onset of myocardial infarction.
Our VIDAS® High sensitive Troponin I assay helps deliver accurate diagnosis of MI in only 2 hours for improved patient outcomes and optimized patient management in the ED.
VIDAS® High sensitive Troponin I is a useful aid to optimize the management of Acute Coronary Syndromes (ACS). VIDAS® HIGH SENSITIVE TROPONIN I to accelerate patient triage with high diagnostic accuracy in only 2 hours.
VIDAS® Solutions
- Reliable and easy-to-use instruments with random access and small footprint.
- Well adapted to rapid response laboratories.
- Factory-calibrated, single-dose tests which reduce the need for additional controls.
- Short time to result.
- Reagents can be used immediately after removal from the refrigerator.
References
1. Bahira Shahim, Chris J Kapelios, Gianluigi Savarese, Lars H Lund, Global Public Health Burden of Heart Failure: An Updated Review, Cardiac Failure Review 2023;9:e11.
https://doi.org/10.15420/cfr.2023.05
2. Lozano R, et al. Lancet.2012;380:2095-128. Bandstein N, et al. J Am Coll Cardiol. 2014;63:2569-78.
3. Mueller C, et al. Eur Heart J. 2015 Aug 29. pii: ehv409.
4. Roffi M, et al. Eur Heart J. 2015 Aug 29. pii: ehv320.
Cardiac Assays
Technical Specifications
| Assays | Reference | Tests per Kit | Code | Time to Result | Measuring Range |
|---|---|---|---|---|---|
| VIDAS® NT-proBNP2 | 30458 30458-30 | 30 or 60 tests | PBN2 | 20 minutes | 15-25,000 pg/ml |
| VIDAS® High sensitive Troponin I | 415386 415386-30 | 30 or 60 tests | TNHS | 20 minutes | 1.5-40,000 pg/mL |
| VIDAS® Myoglobin | 30446 | 30 tests | MYO | 17 minutes | 5-1,000 µg/L |
| VIDAS® CK-MB | 30421 | 30 tests | CKMB | 30 minutes | 0.8-300 ng/mL |
BECAUSE IT MAKES SENSE ON VIDAS®
?qlt=85&ts=1696856626618&dpr=off)
